FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component

By Reuters News

- FDA:

  • FDA APPROVES BELZUTIFAN IN COMBINATION WITH LENVATINIB FOR ADVANCED RENAL CELL CARCINOMA WITH A CLEAR CELL COMPONENT

  • FDA: RECOMMENDED DOSAGE IS 20 MG OF LENVATINIB IN COMBINATION WITH 120 MG OF BELZUTIFAN ONCE DAILY UNTIL DISEASE PROGRESSION OR UNACCEPTABLE TOXICITY

Further company coverage: MRK.N

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk